Skip to main content
Premium Trial:

Request an Annual Quote

Quest Completes Athena Deal

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics today announced the completion of its acquisition of Athena Diagnostics from Thermo Fisher Scientific.

The $740 million deal was announced in late February.

Athena will continue to operate under its own name as an independent business within Quest, and its clinical laboratory in Worcester, Mass., is now the center of excellence in neurology diagnostics for Quest, the Madison, N.J.-based diagnostics testing firm said.

"With this acquisition, Quest Diagnostics has clearly established the leading position in the neurology diagnostics market, "Surya Mohapatra, chairman and CEO of Quest, said in a statement.

Athena generated about $110 million in revenues in 2010 and was part of Thermo Fisher's specialty diagnostics business within its Analytical Technologies segment.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.